

Eric S Kilpatrick

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11309307/publications.pdf>

Version: 2024-02-01

49
papers

2,923
citations

201674

27
h-index

197818

49
g-index

49
all docs

49
docs citations

49
times ranked

3529
citing authors

#	ARTICLE	IF	CITATIONS
1	A1C Variability and the Risk of Microvascular Complications in Type 1 Diabetes. <i>Diabetes Care</i> , 2008, 31, 2198-2202.	8.6	377
2	Insulin Resistance, the Metabolic Syndrome, and Complication Risk in Type 1 Diabetes: "Double diabetes" in the Diabetes Control and Complications Trial. <i>Diabetes Care</i> , 2007, 30, 707-712.	8.6	347
3	The Effect of Glucose Variability on the Risk of Microvascular Complications in Type 1 Diabetes. <i>Diabetes Care</i> , 2006, 29, 1486-1490.	8.6	317
4	Beneficial Effects of Soy Phytoestrogen Intake in Postmenopausal Women With Type 2 Diabetes. <i>Diabetes Care</i> , 2002, 25, 1709-1714.	8.6	308
5	The Effect of Atorvastatin in Patients with Polycystic Ovary Syndrome: A Randomized Double-Blind Placebo-Controlled Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 103-108.	3.6	129
6	Effect of Glucose Variability on the Long-Term Risk of Microvascular Complications in Type 1 Diabetes. <i>Diabetes Care</i> , 2009, 32, 1901-1903.	8.6	124
7	Glycemic Variability: Both Sides of the Story. <i>Diabetes Care</i> , 2013, 36, S272-S275.	8.6	91
8	Paradoxical Changes in Cystatin C and Serum Creatinine in Patients with Hypo- and Hyperthyroidism. <i>Clinical Chemistry</i> , 2003, 49, 680-681.	3.2	88
9	Variability in the Relationship between Mean Plasma Glucose and HbA1c: Implications for the Assessment of Glycemic Control. <i>Clinical Chemistry</i> , 2007, 53, 897-901.	3.2	85
10	The Effect of Soy Phytoestrogen Supplementation on Thyroid Status and Cardiovascular Risk Markers in Patients with Subclinical Hypothyroidism: A Randomized, Double-Blind, Crossover Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 1442-1449.	3.6	81
11	The Role of Blood Pressure Variability in the Development of Nephropathy in Type 1 Diabetes. <i>Diabetes Care</i> , 2010, 33, 2442-2447.	8.6	74
12	Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: A randomized controlled study. <i>Clinical Endocrinology</i> , 2019, 90, 805-813.	2.4	68
13	Current Evidence and Future Perspectives on the Effective Practice of Patient-Centered Laboratory Medicine. <i>Clinical Chemistry</i> , 2015, 61, 589-599.	3.2	61
14	A Randomized, Controlled Trial of Vitamin D Supplementation on Cardiovascular Risk Factors, Hormones, and Liver Markers in Women with Polycystic Ovary Syndrome. <i>Nutrients</i> , 2019, 11, 188.	4.1	61
15	Use of computer terminals on wards to access emergency test results: a retrospective audit. <i>BMJ: British Medical Journal</i> , 2001, 322, 1101-1103.	2.3	59
16	Effects of Isoflavone Dietary Supplementation on Cardiovascular Risk Factors in Type 2 Diabetes. <i>Diabetes Care</i> , 2007, 30, 1871-1873.	8.6	59
17	Atorvastatin Increases 25-Hydroxy Vitamin D Concentrations in Patients with Polycystic Ovary Syndrome. <i>Clinical Chemistry</i> , 2010, 56, 1696-1700.	3.2	48
18	The Diabetes Control and Complications Trial: the gift that keeps giving. <i>Nature Reviews Endocrinology</i> , 2009, 5, 537-545.	9.6	46

#	ARTICLE	IF	CITATIONS
19	Soy Reduces Bone Turnover Markers in Women During Early Menopause: A Randomized Controlled Trial. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 157-164.	2.8	45
20	Effect of Soy in Men With Type 2 Diabetes Mellitus and Subclinical Hypogonadism – A Randomized Controlled Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, jc.2016-2875.	3.6	35
21	The prevalence and metabolic characteristics of polycystic ovary syndrome in the Qatari population. <i>PLoS ONE</i> , 2017, 12, e0181467.	2.5	31
22	Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS). <i>Clinical Endocrinology</i> , 2010, 72, 566-568.	2.4	30
23	Atorvastatin Reduces Malondialdehyde Concentrations in Patients with Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 3951-3955.	3.6	30
24	Arguments for and against the Role of Glucose Variability in the Development of Diabetes Complications. <i>Journal of Diabetes Science and Technology</i> , 2009, 3, 649-655.	2.2	29
25	Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. <i>Annals of Clinical Biochemistry</i> , 2012, 49, 80-85.	1.6	29
26	Appropriate requesting of serum tumour markers. <i>BMJ</i> , The, 2009, 339, b3111-b3111.	6.0	28
27	A national survey of interpretative reporting in the UK. <i>Annals of Clinical Biochemistry</i> , 2011, 48, 317-320.	1.6	28
28	A Fixed Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Reduces Glycemic Fluctuation and Brings More Patients with Type 2 Diabetes Within Blood Glucose Target Ranges. <i>Diabetes Technology and Therapeutics</i> , 2017, 19, 255-264.	4.4	24
29	The Effects of Soy Protein and Cocoa With or Without Isoflavones on Glycemic Control in Type 2 Diabetes. A Double-Blind, Randomized, Placebo-Controlled Study. <i>Frontiers in Endocrinology</i> , 2019, 10, 296.	3.5	22
30	Prediabetes and diabetes in a cohort of Qatari women screened for polycystic ovary syndrome. <i>Scientific Reports</i> , 2018, 8, 3619.	3.3	17
31	Using Multiple Measures of Glycemia to Support Individualized Diabetes Management: Recommendations for Clinicians, Patients, and Payers. <i>Diabetes Technology and Therapeutics</i> , 2012, 14, 973-983.	4.4	16
32	The effects of empagliflozin vs metformin on endothelial microparticles in overweight/obese women with polycystic ovary syndrome. <i>Endocrine Connections</i> , 2020, 9, 563-569.	1.9	15
33	Development of a novel risk prediction and risk stratification score for polycystic ovary syndrome. <i>Clinical Endocrinology</i> , 2019, 90, 162-169.	2.4	13
34	A national audit of estimated glomerular filtration rate and proteinuria reporting in the UK. <i>Annals of Clinical Biochemistry</i> , 2011, 48, 558-561.	1.6	12
35	The Effect of Phytoestrogen on Thyroid in Subclinical Hypothyroidism: Randomized, Double Blind, Crossover Study. <i>Frontiers in Endocrinology</i> , 2018, 9, 531.	3.5	12
36	Dynamic Change in Insulin Resistance Induced by Free Fatty Acids Is Unchanged Though Insulin Sensitivity Improves Following Endurance Exercise in PCOS. <i>Frontiers in Endocrinology</i> , 2018, 9, 592.	3.5	11

#	ARTICLE	IF	CITATIONS
37	Salivary testosterone measurement in women with and without polycystic ovary syndrome. <i>Scientific Reports</i> , 2017, 7, 3589.	3.3	10
38	Soy Protein Improves Cardiovascular Risk in Subclinical Hypothyroidism: A Randomized Double-Blinded Crossover Study. <i>Journal of the Endocrine Society</i> , 2017, 1, 423-430.	0.2	10
39	The Effect of High Dose Isoflavone Supplementation on Serum Reverse T3 in Euthyroid Men With Type 2 Diabetes and Post-menopausal Women. <i>Frontiers in Endocrinology</i> , 2018, 9, 698.	3.5	9
40	Alterations in thyroid status do not affect plasma peptide YY (PYY) and ghrelin concentrations. <i>Clinical Endocrinology</i> , 2008, 68, 836-838.	2.4	6
41	Glycemic Control in the 12 Months following a Change to SI Hemoglobin A1c Reporting Units. <i>Clinical Chemistry</i> , 2013, 59, 1457-1460.	3.2	6
42	Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss. <i>BMC Endocrine Disorders</i> , 2017, 17, 41.	2.2	6
43	Progressive loss of corneal nerve fibers is associated with physical inactivity and glucose lowering medication associated with weight gain in type 2 diabetes. <i>Journal of Diabetes Investigation</i> , 2022, 13, 1703-1710.	2.4	6
44	The effect of thyroid dysfunction on N-terminal pro-B-type natriuretic peptide concentrations. <i>Annals of Clinical Biochemistry</i> , 2006, 43, 184-188.	1.6	5
45	The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome. <i>Endocrine Connections</i> , 2017, 6, 811-816.	1.9	5
46	Relationship between a single measurement at baseline of body mass index, glycated hemoglobin, and the risk of mortality and cardiovascular morbidity in type 2 diabetes mellitus. <i>Cardiovascular Endocrinology and Metabolism</i> , 2020, 9, 177-182.	1.1	5
47	The hitchhiker's guide to research in clinical biochemistry. <i>Clinical Biochemist Reviews</i> , 2010, 31, 25-8.	3.3	3
48	Hypopituitarism presenting as a mixed hyperlipidaemia. <i>Annals of Clinical Biochemistry</i> , 2004, 41, 344-345.	1.6	1
49	A reversible rise in the total cholesterol to HDL ratio in a body builder. <i>British Journal of Diabetes and Vascular Disease</i> , 2012, 12, 200-202.	0.6	1